Effective of Wu Ling Capsule (Xylaria nigripes) in the Treatment of Functional Dyspepsia, Irritable Bowel Syndrome, and Their Overlapping Syndrome

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100054819

Enrollment

Unknown

Registered

2021-12-27

Start date

2019-06-04

Completion date

Unknown

Last updated

2022-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional gastrointestinal disease

Interventions

functional dyspepsia group:Wu Ling Capsule+trimebutine

functional dyspepsia group:trimebutine

irritable bowel syndrome group:Wu Ling Capsule+trimebutine

irritable bowel syndrome group:trimebutine

FD, IBS overlapping syndrome group:Wu Ling Capsule+trimebutine

FD, IBS overlapping syndrome group:trimebutine

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years, willing to join this research and sign the "Informed Consent"; 2. The diagnosis of the patient group met the diagnostic criteria of functional dyspepsia, irritable bowel syndrome, irritable bowel syndrome and functional dyspepsia overlap in Rome IV functional gastrointestinal disease diagnostic criteria. Completion of sleep, mental and gastrointestinal symptoms questionnaires; 3. Screening of alarm symptoms, blood, urine and fecal tests, and gastroscopy to exclude symptom-related organic diseases.

Exclusion criteria

Exclusion criteria: 1. Have a history of severe psychotic episodes; 2. Those who are unable to complete the questionnaire due to intellectual disability, dementia, severe vision and hearing abnormalities or other reasons; 3. History of special drug use (including non-steroidal anti-inflammatory drugs, hormones); 4. Those who have taken acid-suppressing, gastrointestinal motility-promoting, antibiotics, and intestinal flora regulating drugs in the 2 weeks before inclusion; 5. Patients with serious cardiovascular and cerebrovascular diseases, liver, kidney and lung diseases; 6. Patients with acute infectious diseases; 7. Patients under surgery or other stressful situations; 8. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
gastrointestinal symptom;Anxiety;depression;sleeping condition;	—

Countries

China

Contacts

Public ContactLuo Liang

Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine

liangluogi@163.com+86 13819178259

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026